entinostat has been researched along with Disease Models, Animal in 40 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the role of topical Entinostat, a selective inhibitor of histone deacetylases 1 (HDAC1) that has been tested in clinic trials to treat solid tumors and hematological malignancies, in psoriasis therapy." | 4.31 | Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response. ( Jiang, Y; Lai, Y; Lu, S; Wang, L, 2023) |
| "Our findings indicate that single treatment with MS-275 and resveratrol can reduce stroke-mediated brain injury and inflammation observed 2 days after the pMCAO and put the rational to test repeated administration of the drugs." | 3.96 | Neuroprotective epi-drugs quench the inflammatory response and microglial/macrophage activation in a mouse model of permanent brain ischemia. ( Bellucci, A; Benarese, M; Mota, M; Parrella, E; Pizzi, M; Porrini, V; Rhein, S; Schwaninger, M, 2020) |
| "Cancer cachexia is mainly characterized by wasting of skeletal muscles and fat and body weight loss, along with severe complications of major organs like liver, heart, brain and bone." | 1.72 | Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia. ( Bora, V; Goyal, RK; Johar, K; Patel, BM; Patel, D, 2022) |
| "Autism is a neurodevelopmental disorder characterized by social deficits and repetitive behaviors." | 1.48 | Histone deacetylase inhibitor MS-275 restores social and synaptic function in a Shank3-deficient mouse model of autism. ( Duffney, LJ; Liu, A; Ma, K; Matas, E; Qin, L; Yan, Z, 2018) |
| "Treatment with entinostat and azacytidine of ID8 cells in vitro increased mRNA levels of Cd74, Ciita, and H2-Aa, H2-Eb1." | 1.46 | Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. ( Arend, RC; Buchsbaum, DJ; Forero, A; Katre, A; Londoño, A; Meza-Perez, S; Norian, LA; Peabody, JE; Randall, TD; Smith, HJ; Straughn, JM; Turner, TB, 2017) |
| "Pancreatitis is a common inflammation of the pancreas with rising incidence in many countries." | 1.46 | Class I histone deacetylase inhibition improves pancreatitis outcome by limiting leukocyte recruitment and acinar-to-ductal metaplasia. ( Bombardo, M; Chen, R; Graf, R; Haumaitre, C; Malagola, E; Quilichini, E; Reding, T; Saponara, E; Seleznik, GM; Sonda, S; Zabel, A, 2017) |
| " Additionally, the dose-response curve test indicated that MS-275 has a U-shape effect on ethanol self-administration with the dose of 500 µM as the most efficient dose." | 1.42 | The Class I-Specific HDAC Inhibitor MS-275 Decreases Motivation to Consume Alcohol and Relapse in Heavy Drinking Rats. ( Alaux-Cantin, S; Jeanblanc, J; Jeanblanc, V; Lemoine, S; Naassila, M, 2015) |
| "Entinostat treatment was able to reduce the CD44(high)/CD24(low) cell population, ALDH-1 activity, as well as protein and mRNA expression of known TIC markers such as Bmi-1, Nanog, and Oct-4." | 1.42 | Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells. ( Kazi, A; Sabnis, G; Schech, A; Shah, P; Yu, S, 2015) |
| "Entinostat treatment reduced the association of the Her-2 protein with HSP-90, possibly by reducing the stability of Her-2 protein." | 1.39 | HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. ( Brodie, AH; Goloubeva, OG; Kazi, AA; Sabnis, GJ; Shah, P, 2013) |
| "We used the mouse model of transient middle cerebral artery occlusion (MCAO) and primary cortical neurons exposed to oxygen glucose deprivation (OGD)." | 1.39 | Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window. ( Annunziato, L; Benarese, M; Branca, C; Cuomo, O; Lanzillotta, A; Pignataro, G; Pizzi, M; Sarnico, I; Spano, P, 2013) |
| "We reasoned that pretreatment of tumors with HDIs could enhance the replication and spread of OVs within malignancies." | 1.35 | Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. ( Abdelbary, H; Arguello, M; Atkins, H; Bell, JC; Bismar, TA; Breitbach, C; Diallo, JS; Falls, T; Hiscott, J; Kirn, D; Leveille, S; Nguyên, TL; Snoulten, VE; Stojdl, DF; Vähä-Koskela, MJ; Vanderhyden, BC; Werier, J; Yasmeen, A, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (7.50) | 29.6817 |
| 2010's | 28 (70.00) | 24.3611 |
| 2020's | 9 (22.50) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Bora, V | 1 |
| Patel, D | 1 |
| Johar, K | 1 |
| Goyal, RK | 1 |
| Patel, BM | 1 |
| Badrikoohi, M | 1 |
| Esmaeili-Bandboni, A | 1 |
| Babaei, P | 1 |
| Wang, W | 1 |
| Tan, T | 1 |
| Cao, Q | 1 |
| Zhang, F | 1 |
| Rein, B | 1 |
| Duan, WM | 1 |
| Yan, Z | 2 |
| Jiang, Y | 1 |
| Lu, S | 1 |
| Lai, Y | 1 |
| Wang, L | 1 |
| Kim, JA | 1 |
| Crawford, KA | 1 |
| Spada, PA | 1 |
| Martin, LR | 1 |
| Zhang, J | 1 |
| Wong, R | 1 |
| Reid, JM | 1 |
| Stewart, CF | 1 |
| Frank, TM | 1 |
| Liu, Q | 1 |
| Michalek, JE | 2 |
| Keller, C | 2 |
| Li, C | 1 |
| Chen, Y | 2 |
| Zhu, H | 1 |
| Zhang, X | 1 |
| Han, L | 1 |
| Zhao, Z | 1 |
| Wang, J | 1 |
| Ning, L | 1 |
| Zhou, W | 1 |
| Lu, C | 1 |
| Xu, L | 1 |
| Sang, J | 1 |
| Feng, Z | 1 |
| Zhang, Y | 2 |
| Lou, X | 1 |
| Bo, X | 1 |
| Zhu, B | 1 |
| Yu, C | 1 |
| Zheng, M | 1 |
| Li, Y | 2 |
| Sun, J | 1 |
| Shen, Z | 1 |
| Lu, Z | 1 |
| Zou, J | 1 |
| Li, S | 1 |
| Topper, MJ | 1 |
| Tao, Y | 1 |
| Zhang, H | 2 |
| Jiao, X | 1 |
| Xie, W | 1 |
| Kong, X | 1 |
| Vaz, M | 1 |
| Li, H | 1 |
| Cai, Y | 1 |
| Xia, L | 1 |
| Huang, P | 1 |
| Rodgers, K | 1 |
| Lee, B | 1 |
| Riemer, JB | 1 |
| Day, CP | 1 |
| Yen, RC | 1 |
| Cui, Y | 1 |
| Wang, Y | 2 |
| Zhang, W | 1 |
| Easwaran, H | 1 |
| Hulbert, A | 1 |
| Kim, K | 1 |
| Juergens, RA | 1 |
| Yang, SC | 1 |
| Battafarano, RJ | 1 |
| Bush, EL | 1 |
| Broderick, SR | 1 |
| Cattaneo, SM | 1 |
| Brahmer, JR | 1 |
| Rudin, CM | 1 |
| Wrangle, J | 1 |
| Mei, Y | 1 |
| Kim, YJ | 1 |
| Zhang, B | 1 |
| Wang, KK | 1 |
| Forde, PM | 1 |
| Margolick, JB | 1 |
| Nelkin, BD | 1 |
| Zahnow, CA | 1 |
| Pardoll, DM | 1 |
| Housseau, F | 1 |
| Baylin, SB | 1 |
| Shen, L | 3 |
| Brock, MV | 1 |
| Mota, M | 1 |
| Porrini, V | 1 |
| Parrella, E | 1 |
| Benarese, M | 2 |
| Bellucci, A | 1 |
| Rhein, S | 1 |
| Schwaninger, M | 1 |
| Pizzi, M | 2 |
| Sarker, P | 1 |
| Banik, A | 1 |
| Stromberg, R | 1 |
| Gudmundsson, GH | 1 |
| Raqib, R | 1 |
| Agerberth, B | 1 |
| Turner, TB | 1 |
| Meza-Perez, S | 1 |
| Londoño, A | 1 |
| Katre, A | 1 |
| Peabody, JE | 1 |
| Smith, HJ | 1 |
| Forero, A | 1 |
| Norian, LA | 1 |
| Straughn, JM | 1 |
| Buchsbaum, DJ | 1 |
| Randall, TD | 1 |
| Arend, RC | 1 |
| Orillion, A | 1 |
| Hashimoto, A | 1 |
| Damayanti, N | 1 |
| Adelaiye-Ogala, R | 1 |
| Arisa, S | 1 |
| Chintala, S | 1 |
| Ordentlich, P | 2 |
| Kao, C | 1 |
| Elzey, B | 1 |
| Gabrilovich, D | 1 |
| Pili, R | 2 |
| Bombardo, M | 1 |
| Saponara, E | 1 |
| Malagola, E | 1 |
| Chen, R | 1 |
| Seleznik, GM | 1 |
| Haumaitre, C | 1 |
| Quilichini, E | 1 |
| Zabel, A | 1 |
| Reding, T | 1 |
| Graf, R | 1 |
| Sonda, S | 1 |
| Yin, X | 1 |
| Wu, Q | 1 |
| Monga, J | 1 |
| Xie, E | 1 |
| Wang, H | 1 |
| Wang, S | 1 |
| Wang, ZY | 1 |
| Zhou, T | 1 |
| Shi, Y | 1 |
| Rogers, J | 1 |
| Lin, H | 1 |
| Min, J | 1 |
| Wang, F | 2 |
| Ma, K | 1 |
| Qin, L | 1 |
| Matas, E | 1 |
| Duffney, LJ | 1 |
| Liu, A | 1 |
| Culley, KL | 1 |
| Hui, W | 1 |
| Barter, MJ | 1 |
| Davidson, RK | 1 |
| Swingler, TE | 1 |
| Destrument, AP | 1 |
| Scott, JL | 1 |
| Donell, ST | 1 |
| Fenwick, S | 1 |
| Rowan, AD | 1 |
| Young, DA | 1 |
| Clark, IM | 1 |
| Denk, F | 1 |
| Huang, W | 1 |
| Sidders, B | 1 |
| Bithell, A | 1 |
| Crow, M | 1 |
| Grist, J | 1 |
| Sharma, S | 1 |
| Ziemek, D | 1 |
| Rice, ASC | 1 |
| Buckley, NJ | 1 |
| McMahon, SB | 1 |
| Sabnis, GJ | 1 |
| Goloubeva, OG | 1 |
| Kazi, AA | 1 |
| Shah, P | 2 |
| Brodie, AH | 1 |
| Murphy, SP | 1 |
| Lee, RJ | 1 |
| McClean, ME | 1 |
| Pemberton, HE | 1 |
| Uo, T | 1 |
| Morrison, RS | 1 |
| Bastian, C | 1 |
| Baltan, S | 1 |
| Lee, J | 1 |
| Bartholomeusz, C | 1 |
| Mansour, O | 1 |
| Humphries, J | 1 |
| Hortobagyi, GN | 1 |
| Ueno, NT | 1 |
| Abraham, J | 1 |
| Nuñez-Álvarez, Y | 1 |
| Hettmer, S | 1 |
| Carrió, E | 1 |
| Chen, HI | 1 |
| Nishijo, K | 1 |
| Huang, ET | 1 |
| Prajapati, SI | 1 |
| Walker, RL | 1 |
| Davis, S | 1 |
| Rebeles, J | 1 |
| Wiebush, H | 1 |
| McCleish, AT | 1 |
| Hampton, ST | 1 |
| Bjornson, CR | 1 |
| Brack, AS | 1 |
| Wagers, AJ | 1 |
| Rando, TA | 1 |
| Capecchi, MR | 1 |
| Marini, FC | 1 |
| Ehler, BR | 1 |
| Zarzabal, LA | 1 |
| Goros, MW | 1 |
| Meltzer, PS | 1 |
| Langenau, DM | 1 |
| LeGallo, RD | 1 |
| Mansoor, A | 1 |
| Suelves, M | 1 |
| Rubin, BP | 1 |
| Kettyle, LM | 1 |
| Liberante, FG | 1 |
| Thompson, A | 1 |
| Zhao, T | 1 |
| Liu, B | 1 |
| Halaweish, I | 1 |
| Mazitschek, R | 1 |
| Duan, X | 1 |
| Alam, HB | 1 |
| Jeanblanc, J | 1 |
| Lemoine, S | 1 |
| Jeanblanc, V | 1 |
| Alaux-Cantin, S | 1 |
| Naassila, M | 1 |
| Cantley, MD | 1 |
| Fairlie, DP | 1 |
| Bartold, PM | 1 |
| Marino, V | 1 |
| Gupta, PK | 1 |
| Haynes, DR | 1 |
| Covington, HE | 2 |
| Maze, I | 2 |
| Vialou, V | 2 |
| Nestler, EJ | 2 |
| Schech, A | 1 |
| Kazi, A | 1 |
| Yu, S | 1 |
| Sabnis, G | 1 |
| Pinho, BR | 1 |
| Reis, SD | 1 |
| Guedes-Dias, P | 1 |
| Leitão-Rocha, A | 1 |
| Quintas, C | 1 |
| Valentão, P | 1 |
| Andrade, PB | 1 |
| Santos, MM | 1 |
| Oliveira, JM | 1 |
| Yong, KJ | 1 |
| Li, A | 1 |
| Ou, WB | 1 |
| Hong, CK | 1 |
| Zhao, W | 1 |
| Tatetsu, H | 1 |
| Yan, B | 1 |
| Qi, L | 1 |
| Fletcher, JA | 1 |
| Yang, H | 1 |
| Soo, R | 1 |
| Tenen, DG | 1 |
| Chai, L | 1 |
| Hiroshima, Y | 1 |
| Maawy, A | 1 |
| Zhang, N | 1 |
| Murakami, T | 1 |
| Chishima, T | 1 |
| Tanaka, K | 1 |
| Ichikawa, Y | 1 |
| Bouvet, M | 1 |
| Endo, I | 1 |
| Hoffman, RM | 1 |
| Ferrari, A | 1 |
| Fiorino, E | 1 |
| Longo, R | 1 |
| Barilla, S | 1 |
| Mitro, N | 1 |
| Cermenati, G | 1 |
| Giudici, M | 1 |
| Caruso, D | 1 |
| Mai, A | 1 |
| Guerrini, U | 1 |
| De Fabiani, E | 1 |
| Crestani, M | 1 |
| Nguyên, TL | 1 |
| Abdelbary, H | 1 |
| Arguello, M | 1 |
| Breitbach, C | 1 |
| Leveille, S | 1 |
| Diallo, JS | 1 |
| Yasmeen, A | 1 |
| Bismar, TA | 1 |
| Kirn, D | 1 |
| Falls, T | 1 |
| Snoulten, VE | 1 |
| Vanderhyden, BC | 1 |
| Werier, J | 1 |
| Atkins, H | 1 |
| Vähä-Koskela, MJ | 1 |
| Stojdl, DF | 1 |
| Bell, JC | 1 |
| Hiscott, J | 1 |
| LaPlant, QC | 1 |
| Vialou, VF | 1 |
| Ohnishi, YN | 1 |
| Berton, O | 1 |
| Fass, DM | 1 |
| Renthal, W | 1 |
| Rush, AJ | 1 |
| Wu, EY | 1 |
| Ghose, S | 1 |
| Krishnan, V | 1 |
| Russo, SJ | 1 |
| Tamminga, C | 1 |
| Haggarty, SJ | 1 |
| Zhang, ZY | 2 |
| Schluesener, HJ | 2 |
| Cavasin, MA | 1 |
| Demos-Davies, K | 1 |
| Horn, TR | 1 |
| Walker, LA | 1 |
| Lemon, DD | 1 |
| Birdsey, N | 1 |
| Weiser-Evans, MC | 1 |
| Harral, J | 1 |
| Irwin, DC | 1 |
| Anwar, A | 1 |
| Yeager, ME | 1 |
| Li, M | 1 |
| Watson, PA | 1 |
| Nemenoff, RA | 1 |
| Buttrick, PM | 1 |
| Stenmark, KR | 1 |
| McKinsey, TA | 1 |
| Ciesielski, M | 1 |
| Ramakrishnan, S | 1 |
| Miles, KM | 1 |
| Ellis, L | 1 |
| Sotomayor, P | 1 |
| Shrikant, P | 1 |
| Fenstermaker, R | 1 |
| Lanzillotta, A | 1 |
| Pignataro, G | 1 |
| Branca, C | 1 |
| Cuomo, O | 1 |
| Sarnico, I | 1 |
| Annunziato, L | 1 |
| Spano, P | 1 |
| Eyüpoglu, IY | 1 |
| Hahnen, E | 1 |
| Tränkle, C | 1 |
| Savaskan, NE | 1 |
| Siebzehnrübl, FA | 1 |
| Buslei, R | 1 |
| Lemke, D | 1 |
| Wick, W | 1 |
| Fahlbusch, R | 1 |
| Blümcke, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial of Tucidinostat in Combination With Fulvestrant in Patients With Hormone-receptor Positive Advanced Breast Cancer[NCT04999540] | Phase 2 | 73 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| Clinical, Neurophysiological and Genetical Predictors of Consciousness Recovery and Functional Outcomes After Severe Acquired Brain Injuries[NCT04495192] | 520 participants (Anticipated) | Observational [Patient Registry] | 2020-06-09 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
40 other studies available for entinostat and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia.
Topics: Animals; Benzamides; Butyric Acid; Cachexia; Cell Line, Tumor; Disease Models, Animal; Disease Progr | 2022 |
Simultaneous administration of bromodomain and histone deacetylase I inhibitors alleviates cognition deficit in Alzheimer's model of rats.
Topics: Alzheimer Disease; Animals; Azepines; Behavior, Animal; Benzamides; CREB-Binding Protein; Disease Mo | 2022 |
Histone Deacetylase Inhibition Restores Behavioral and Synaptic Function in a Mouse Model of 16p11.2 Deletion.
Topics: Animals; Chromosome Deletion; Disease Models, Animal; Histone Deacetylase Inhibitors; Histone Deacet | 2022 |
Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response.
Topics: Animals; Disease Models, Animal; Eczema; Histone Deacetylase 1; Humans; Imiquimod; Interleukin-17; M | 2023 |
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Animals; Benzamides; Disease Models, Animal; Enoxac | 2023 |
Inhibition of Histone Deacetylation by MS-275 Alleviates Colitis by Activating the Vitamin D Receptor.
Topics: Acetylation; Animals; Apoptosis; Benzamides; Cells, Cultured; Colitis; Colitis, Ulcerative; Disease | 2020 |
Epigenetic therapy inhibits metastases by disrupting premetastatic niches.
Topics: Animals; Azacitidine; Benzamides; Cell Differentiation; Cell Movement; Chemotherapy, Adjuvant; Disea | 2020 |
Neuroprotective epi-drugs quench the inflammatory response and microglial/macrophage activation in a mouse model of permanent brain ischemia.
Topics: Animals; Antioxidants; Benzamides; Disease Models, Animal; Histone Deacetylase Inhibitors; Infarctio | 2020 |
Treatment with Entinostat Heals Experimental Cholera by Affecting Physical and Chemical Barrier Functions of Intestinal Epithelia.
Topics: Administration, Oral; Animals; Antimicrobial Cationic Peptides; Benzamides; Cathelicidins; Cholera; | 2017 |
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Cell Line, Tumor; Disease Models, | 2017 |
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
Topics: Animals; Benzamides; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Disease Models, Animal; | 2017 |
Class I histone deacetylase inhibition improves pancreatitis outcome by limiting leukocyte recruitment and acinar-to-ductal metaplasia.
Topics: Acinar Cells; Acute Disease; Animals; Autoimmune Diseases; Benzamides; Disease Models, Animal; ErbB | 2017 |
HDAC1 Governs Iron Homeostasis Independent of Histone Deacetylation in Iron-Overload Murine Models.
Topics: Acetylation; Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Histone | 2018 |
Histone deacetylase inhibitor MS-275 restores social and synaptic function in a Shank3-deficient mouse model of autism.
Topics: Actins; Animals; Autistic Disorder; Benzamides; Brain; Cell Membrane; Cells, Cultured; Disease Model | 2018 |
Class I histone deacetylase inhibition modulates metalloproteinase expression and blocks cytokine-induced cartilage degradation.
Topics: Animals; Benzamides; Cattle; Cell Line, Tumor; Cells, Cultured; Chondrocytes; Disease Models, Animal | 2013 |
HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain.
Topics: Animals; Anti-Retroviral Agents; Benzamides; Disease Models, Animal; Dose-Response Relationship, Dru | 2013 |
HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Topics: Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Benzamides; Disease Models, Animal; | 2013 |
MS-275, a class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury.
Topics: Action Potentials; Animals; Benzamides; Blotting, Western; Brain Ischemia; Disease Models, Animal; H | 2014 |
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; Breast Neoplasms; Cell Li | 2014 |
Lineage of origin in rhabdomyosarcoma informs pharmacological response.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Lineage; Disease Models, Animal; | 2014 |
Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Databases, Genetic; Disease Models, An | 2014 |
Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model.
Topics: Animals; Benzamides; Blotting, Western; Cytokines; Dimethyl Sulfoxide; Disease Models, Animal; Enzym | 2015 |
The Class I-Specific HDAC Inhibitor MS-275 Decreases Motivation to Consume Alcohol and Relapse in Heavy Drinking Rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Benzamides; Disease Models, Animal; Dose-Re | 2015 |
Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis.
Topics: Animals; Arthritis, Experimental; Benzamides; Bone Resorption; Cells, Cultured; Chemokines; Cytokine | 2015 |
Antidepressant action of HDAC inhibition in the prefrontal cortex.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Benz | 2015 |
Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Biomarkers; CD24 Antigen; Cell Line, Tumor; Disease Mode | 2015 |
Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Behavior, Animal; Benzamides; Diencephalon; Disease Models, An | 2016 |
Targeting SALL4 by entinostat in lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Disease Models, Animal; | 2016 |
Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy.
Topics: Animals; Benzamides; Disease Models, Animal; Female; Humans; Mice; Neoplasm Metastasis; Precision Me | 2016 |
Attenuation of diet-induced obesity and induction of white fat browning with a chemical inhibitor of histone deacetylases.
Topics: Adipocytes, Brown; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Benzamides; Diet, High-Fat | 2017 |
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Topics: Animals; Benzamides; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; Female; Histone De | 2008 |
Antidepressant actions of histone deacetylase inhibitors.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Depression; Dise | 2009 |
[Histone acetylation, gene regulation and depression].
Topics: Acetylation; Animals; Antidepressive Agents; Benzamides; Depressive Disorder; Disease Models, Animal | 2010 |
HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis.
Topics: Animals; Autoimmune Diseases; Benzamides; Disease Models, Animal; Histone Deacetylase Inhibitors; Im | 2012 |
Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.
Topics: Animals; Benzamides; Blood Pressure; Cell Proliferation; Cells, Cultured; Disease Models, Animal; He | 2012 |
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Topics: Acetylation; Animals; Benzamides; Carcinoma, Renal Cell; Castration; CD8-Positive T-Lymphocytes; Dis | 2012 |
Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window.
Topics: Acetylation; Animals; Benzamides; Brain; Brain Ischemia; Cell Hypoxia; Disease Models, Animal; Epige | 2013 |
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Topics: Administration, Oral; Alzheimer Disease; Amyloidosis; Animals; Behavior, Animal; Benzamides; Brain; | 2013 |
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Brain; Cell Adhesion Molecules, Neu | 2006 |